Houston is a top city for female entrepreneurs, according to a recent study. Getty Images

Houston's innovation ecosystem has been booming with news, and it's likely some might have fallen through the cracks.

For this roundup of short stories within Houston innovation, Houston is recognized for its female-friendly business community, Texas ranks as top for gig economy, the latest Chevron investment is in nuclear energy, and more.

Houston named among top cities for female entrepreneurs

Houston ranked No. 11 on a new study on top cities for female business owners. Via fundera.com

According to a new study from Fundera, Houston ranks among the top 15 cities for female entrepreneurs in the United States. The Bayou City came in at No. 11 based on data pulled from The American Community Survey from the U.S. Census Bureau as well as the Tax Foundation. Metrics included:

  • Percent of self-employed business owners who are women — 18 percent of total score.
  • Percent of women employed in their own business — 18 percent of total score.
  • Earnings gap between male and female business owners — 18 percent of total score.
  • Housing cost as a percent of earnings for female entrepreneurs — 18 percent of total score.
  • Percent of residents with bachelor's degree, denoting high-skilled workforce — 9 percent of total score.
  • Job growth — 9 percent of total score.
  • Tax rates — 9 percent of total score.

"One of the most diverse cities in the country, Houston is also good to its women entrepreneur population," the study reads. "Its biggest strength here, however, may be in its job growth numbers, which were likely impacted by 2020's coronavirus pandemic. It remains to be seen whether the city's strong economic numbers will continue in the years to come."

Lubbock, the only other Texas city to crack the top 15, came in at No. 13.

Galen Data and Zibrio team up with new partnership

A Houston company's balance tracking technology is tapping into another Houston company's cloud technology. Photo courtesy of Zibrio

Houston-based tech companies, Galen Data and Zibrio, have announced a new medical device partnership. Zibrio's SmartScale, which can measure and track physical balance to identify an person's chance of falling, will be able to leverage the Galen CloudTM in order to securely connect data from the device with a patient's physician to support remote patient care.

"Our partnership with Zibrio is a case study in helping an early stage medical device company focus on what they do best," says Galen Data CEO Chris DuPont in a news release. "Galen Data provided outside expertise that has saved Zibrio the needless cost and burden of designing a cloud solution from scratch."

According to the release, the CDC reports that 28 percent of individuals over 65 fall each year, and falls are the leading cause of accidental death in those over 65. Amid the pandemic, the Australian PT Association found an increase in fall right of up to 30 percent.

"With COVID-19 impacting activities of older adults, it was even more critical to find a cost-effective solution to better track, manage, and analyze balance data from our SmartScale," says Zibrio founder and CEO, Katharine Forth, in the release.

IGNITE Madness startup applications close Sept. 4

Ignite Healthcare Network, a health tech startup group that promotes and advances female entrepreneurs, is closing startup applications for its October 22 and 29 event, Ignite Madness. The competition mimics a March Madness-style bracket and will be judged by 10 judges.

The brackets include:

  1. Mental /Behavioral Health
  2. Telemedicine/Remote Patient Monitoring
  3. Medical Devices
  4. Patient Engagement
  5. Employee Wellness
  6. Population Health/Analytics
  7. Femtech/Women's Health
  8. WILDCARD: Other Disruptive Solutions
Apply online for up to $300,000 in cash and prizes.

Texas named the 6th best state for freelance and gig workers

Gig workers are welcome in Texas. Screenshot via directlyapply.com

A job discovery platform, DirectlyApply, has identified the best gig economies to work in and Texas ranked as No. 6. The study looked at nine cost and job opportunity factors, which included the cost of living, the number of restaurants and attractions, the number of advertised gig roles, etc.

Texas has a reported 4,859 gig jobs and 16 gig companies operating locally, and the state sports an average gas price of $0.63 a liter and $1,422 a month to rent an apartment. New York, Florida, California, Ohio, and Illinois ranked ahead of Texas, respectively. The full study is available online.

Adapt2 Solutions recognized with award

Jason Kram is the executive vice president of Adapt2 Solutions. Photo courtesy of Adapt2 Solutions

Houston AI software company, Adapt2 Solutions, has been selected as the winner of the "Best AI Solution for Big Data" award in the 2020 AI Breakthrough Awards program conducted by AI Breakthrough. The awards recognize artificial intelligence and machine learning innovation. This year, the contest saw more than 2,750 nominations from over 15 different countries throughout the world, according to a news release.

"Energy enterprises are dealing with an increasingly complex and ever-changing landscape, including increased renewables, volatile markets, and increased pace of technology innovation for each of the commodity market," says James Johnson, managing director of AI Breakthrough, in the release.

"Adapt2 Solutions is in a unique position to support energy companies with powerful artificial intelligence technology to help their operations to automate, optimize and maintain a competitive advantage. We want to recognize this achievement by awarding them with 'Best AI Solution for Big Data' and we extend a hearty congratulations to the entire Adapt2 team on their well-deserved industry recognition."

The win comes at a strategic time for the company. Adapt2's predictive analytics models forecast unexpected fluctuations in power capacity. Amid the pandemic, this technology enables energy companies to map out demand at a time when they're balancing strained revenue and squeezed spending is paramount, Executive Vice President Jason Kram previously told InnovationMap.

"In times of disruption, big data can inform decision-making for energy companies to optimize energy-market operations with timely and reliable data," Kram says.

Houston Methodist introduces contactless temperature screening

Houston Methodist has set up over a hundred contactless temp checks across its facilities. Photo courtesy of Houston Methodist

Houston Methodist has incorporated new technology from care.ai, an AI-powered temperature monitoring platform, to conduct contactless temperature checks for visitors across 100 locations throughout eight hospitals and 36 physician clinics.

Upon entrance to designated areas, visitors stand in front of a tablet that scans an individual's temperature through the use of thermal technology aimed at the forehead. The technology aims to speed up screening measures and free up staff from the checkpoints. Should a visitor have an elevated skin temperature out of normal range, Methodist staff is contacted.

Chevron invests in nuclear fusion startup

The latest investment from CTV is in nuclear energy. Photo via chevron.com/technology/technology-ventures

Chevron's investment arm, Chevron Technology Ventures, recently announced an investment in Seattle-based Zap Energy Inc., which is working on a modular nuclear reactor. CTV sees nuclear energy as a promising avenue for innovation "across the globe access to affordable, reliable, and ever-cleaner energy," according to a news release.

"We see fusion technology as a promising low-carbon future energy source," says Barbara Burger, president of CTV, in a release. "Our Future Energy Fund investment in Zap Energy adds to Chevron's portfolio of companies we believe are likely to have a role in the energy transition."

This Series A investment is the 10th for Chevron's Future Energy Fund, which focuses on investments in companies that enable macro decarbonization, the mobility-energy nexus, and energy decentralization.

"Our Future Energy Fund investments provide us with strategic insight into power generation markets and potentially disruptive impacts of innovative approaches, like fusion, geothermal, wind, and solar, on the conventional power value chain," says Burger.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Greentown Labs names Lawson Gow as its new Houston leader

head of hou

Greentown Labs has named Lawson Gow as its Head of Houston.

Gow is the founder of The Cannon, a coworking space with seven locations in the Houston area, with additional partner spaces. He also recently served as managing partner at Houston-based investment and advisory firm Helium Capital. Gow is the son of David Gow, founder of Energy Capital's parent company, Gow Media.

According to Greentown, Gow will "enhance the founder experience, cultivate strategic partnerships, and accelerate climatetech solutions" in his new role.

“I couldn’t be more excited to join Greentown at this critical moment for the energy transition,” Gow said in a news release. “Greentown has a fantastic track record of supporting entrepreneurs in Houston, Boston, and beyond, and I am eager to keep advancing our mission in the energy transition capital of the world.”

Gow has also held analyst, strategy and advising roles since graduating from Rice University.

“We are thrilled to welcome Lawson to our leadership team,” Georgina Campbell Flatter, CEO of Greentown Labs, added in the release. “Lawson has spent his career building community and championing entrepreneurs, and we look forward to him deepening Greentown’s support of climate and energy startups as our Head of Houston.”

Gow is the latest addition to a series of new hires at Greentown Labs following a leadership shakeup.

Flatter was named as the organization's new CEO in February, replacing Kevin Dutt, Greentown’s interim CEO, who replaced Kevin Knobloch after he announced that he would step down in July 2024 after less than a year in the role.

Greentown also named Naheed Malik its new CFO in January.

Timmeko Moore Love was named the first Houston general manager and senior vice president of Greentown Labs. According to LinkedIn, she left the role in January.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.